{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:15:12Z","timestamp":1777644912216,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s13730-019-00375-7","type":"journal-article","created":{"date-parts":[[2019,1,13]],"date-time":"2019-01-13T23:58:24Z","timestamp":1547423904000},"page":"112-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tolvaptan corrects hyponatremia and relieves the burden of fluid\/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases"],"prefix":"10.1007","volume":"8","author":[{"given":"Keiko","family":"Kai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-7418","authenticated-orcid":false,"given":"Naoto","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Koitabashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"375_CR1","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.1986.4.8.1191","volume":"4","author":"AF List","year":"1986","unstructured":"List AF, Hainsworth JD, Davis BW, Hande KR, Greco FA, Johnson DH. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol. 1986;4:1191\u20138.","journal-title":"J Clin Oncol"},{"key":"375_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2796.1995.tb00907.x","volume":"238","author":"JB S\u00f8rensen","year":"1995","unstructured":"S\u00f8rensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med. 1995;238:97\u2013110.","journal-title":"J Intern Med"},{"key":"375_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1634\/theoncologist.2011-0400","volume":"17","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012;17:756\u201365.","journal-title":"Oncologist"},{"key":"375_CR4","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","volume":"24","author":"R Govindan","year":"2006","unstructured":"Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539\u201344.","journal-title":"J Clin Oncol"},{"key":"375_CR5","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00520-017-3638-3","volume":"25","author":"V Burst","year":"2017","unstructured":"Burst V, Grundmann F, Kubacki T, Greenberg A, Rudolf D, Salahudeen A, Verbalis J, Groh\u00e9 C. Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study. Support Care Cancer. 2017;25:2275\u201383.","journal-title":"Support Care Cancer"},{"key":"375_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2009.05.015","volume":"68","author":"O Hansen","year":"2010","unstructured":"Hansen O, S\u00f8rensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer. 2010;68:111\u20134.","journal-title":"Lung Cancer"},{"key":"375_CR7","first-page":"860","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsuji- mae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M,, Mori T, Tsuji-moto G. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"375_CR8","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. SALT Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u2013112.","journal-title":"N Engl J Med"},{"key":"375_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.rmed.2012.02.010","volume":"106","author":"A Hermes","year":"2012","unstructured":"Hermes A, Waschki B, Reck M. Hyponatremia as prognostic factor in small cell lung cancer\u2014a retrospective single institution analysis. Respir Med. 2012;106:900\u20134.","journal-title":"Respir Med"},{"key":"375_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2466-13-55","volume":"13","author":"C Petereit","year":"2013","unstructured":"Petereit C, Zaba O, Teber I, L\u00fcders H, Groh\u00e9 C. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm Med. 2013;13:55.","journal-title":"BMC Pulm Med"},{"key":"375_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12902-016-0104-z","volume":"16","author":"C Jamookeeah","year":"2016","unstructured":"Jamookeeah C, Robinson P, O\u2019Reilly K, Lundberg J, Gisby M, L\u00e4ndin M, Skov J, Trueman D. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. BMC Endocr Disord. 2016;16:22.","journal-title":"BMC Endocr Disord"},{"key":"375_CR12","unstructured":"Guidance on Diagnosis and Treatment of Vasopressin. Hyperactivity (SIADH), (Revised in 2010). Research grant for Health Labor Sciences Research grant, research project on overcoming intractable diseases, research on interphrenia pituitary dysfunction (lead researcher: Yutaka Oiso)."},{"key":"375_CR13","doi-asserted-by":"crossref","unstructured":"Petereit C, Zaba O, Teber I, Groh\u00e9 C. Is hyponatremia a prognostic marker of survival for lung cancer? Pneumologie. 2011;65:565\u201371. \n                    http:\/\/square.umin.ac.jp\/kasuitai\/doctor\/guidance\/SIADH.pdf\n                    \n                  . Accessed 27 March 2018.","DOI":"10.1055\/s-0030-1256668"},{"key":"375_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.04.005","volume":"96","author":"C Groh\u00e9","year":"2015","unstructured":"Groh\u00e9 C, Berardi R, Burst V. Hyponatraemia\u2014SIADH in lung cancer diagnostic and treatment algorithms. Crit Rev Oncol Hematol. 2015;96:1\u20138.","journal-title":"Crit Rev Oncol Hematol"},{"key":"375_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1017\/S0959259814000197","volume":"25","author":"I Runkle","year":"2015","unstructured":"Runkle I, G\u00f3mez-Hoyos E, Cuesta-Hern\u00e1ndez M, et al. Hyponatraemia in older patients: a clinical and practical approach. Rev Clin Gerontol. 2015;25:31\u201352.","journal-title":"Rev Clin Gerontol"},{"key":"375_CR16","unstructured":"Kusuri-no-Shiori. (Drug information sheet), Otsuka Pharmaceutical Co., Ltd. SAMSCA tablets 7.5\u00a0mg (volume overload in heart failure and body fluid retention in hepatic cirrhosis). \n                    http:\/\/www.rad-ar.or.jp\/siori\/english\/kekka.cgi?n=34699\n                    \n                   (2018). Revised Oct 2018."},{"key":"375_CR17","unstructured":"Kusuri-no-Shiori. (Drug information sheet), Otsuka Pharmaceutical Co., Ltd. SAMSCA tablets 7.5 mg (autosomal dominant polycystic kidney disease). \n                    http:\/\/www.rad-ar.or.jp\/siori\/english\/kekka.cgi?n=34698\n                    \n                   (2018). Revised March 2018."}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-019-00375-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-019-00375-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-019-00375-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T19:21:41Z","timestamp":1578943301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-019-00375-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1007\/s13730-019-00375-7","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"10 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Honoraria: Naoto Tominaga (Otsuka Pharmaceutical), and Yugo Shibagaki (Novartis pharma, Otsuka Pharmaceutical). Research funding: Yugo Shibagaki (Teijin Pharma, Otsuka Pharmasuitical, Takeda, Kyowa-Hakko Kirin).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The design of this report was approved and the requirement for informed consent was waived by our institutional review board (No. 3950).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}